Jae‐Lyun Lee

25.8k total citations · 5 hit papers
394 papers, 11.4k citations indexed

About

Jae‐Lyun Lee is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Jae‐Lyun Lee has authored 394 papers receiving a total of 11.4k indexed citations (citations by other indexed papers that have themselves been cited), including 235 papers in Pulmonary and Respiratory Medicine, 190 papers in Oncology and 142 papers in Surgery. Recurrent topics in Jae‐Lyun Lee's work include Renal cell carcinoma treatment (149 papers), Bladder and Urothelial Cancer Treatments (99 papers) and Renal and related cancers (83 papers). Jae‐Lyun Lee is often cited by papers focused on Renal cell carcinoma treatment (149 papers), Bladder and Urothelial Cancer Treatments (99 papers) and Renal and related cancers (83 papers). Jae‐Lyun Lee collaborates with scholars based in South Korea, United States and Canada. Jae‐Lyun Lee's co-authors include Toni K. Choueiri, Daniel P. Petrylak, Nicholas J. Vogelzang, Yoon‐Koo Kang, Rodolfo F. Perini, Andrea Necchi, Min‐Hee Ryu, David I. Quinn, Howard Gurney and Tae Won Kim and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Jae‐Lyun Lee

370 papers receiving 11.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

2017 2.4k citations Joaquim Bellmunt, Ronald de Wit et al. New England Journal of Medicine profile →
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

2021 670 citations Jonathan E. Rosenberg, Jae‐Lyun Lee et al. New England Journal of Medicine profile →
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

2017 664 citations Jae‐Lyun Lee, Nicholas J. Vogelzang et al. JAMA Oncology profile →
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma

2021 183 citations David F. McDermott, Jae‐Lyun Lee et al. Journal of Clinical Oncology profile →
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

2021 175 citations Daniel P. Petrylak, Jae‐Lyun Lee et al. profile →

Peers

Countries citing papers authored by Jae‐Lyun Lee

Since Specialization

Citations

This map shows the geographic impact of Jae‐Lyun Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jae‐Lyun Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jae‐Lyun Lee more than expected).

Fields of papers citing papers by Jae‐Lyun Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jae‐Lyun Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jae‐Lyun Lee. The network helps show where Jae‐Lyun Lee may publish in the future.

Co-authorship network of co-authors of Jae‐Lyun Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Jae‐Lyun Lee. A scholar is included among the top collaborators of Jae‐Lyun Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jae‐Lyun Lee. Jae‐Lyun Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1Pembrolizumab plus lenvatinib for previously untreated advanced non–clear cell renal cell carcinoma: 3-year follow-up of the phase 2 KEYNOTE-B61 study 2025 ·The Oncologist ·Laurence Albigès, Howard Gurney, Jae‐Lyun Lee, Vagif Atduev, Cristina Suárez, Miguel Ángel Climent, David Pook, Piotr Tomczak, Philippe Barthélémy, Craig Gedye, Louis Lacombe, Thomas Ferguson, V.P. Stus, Paweł Wiechno, Mustafa Erman, (unknown), (unknown), (unknown), (unknown), Martin H. Voss	0
2	Limitation of the current Lin-Weiss-Bisceglia criteria in predicting poor prognosis in oncocytic adrenocortical neoplasms of uncertain malignant potential and oncocytoma diagnosed by the Lin-Weiss-Bisceglia criteria 2025 ·Therapeutic Advances in Endocrinology and Metabolism ·(unknown), Hyejin Han, D Kwon, (unknown), (unknown), Won Woong Kim, Yu‐Mi Lee, Seung Hun Lee, Jung‐Min Koh, Jae‐Lyun Lee, (unknown), Dong Eun Song, Tae‐Yon Sung	1
3	Body composition and immunotherapy outcomes in patients with advanced urothelial carcinoma. 2025 ·Journal of Clinical Oncology ·Sojin Kim, (unknown), Inkeun Park, Jae‐Lyun Lee, Hyehyun Jeong, Yousun Ko, Kyung Won Kim, Sun Young Kim	0
4	Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): Safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study. 2025 ·Journal of Clinical Oncology ·Toni K. Choueiri, Jae‐Lyun Lee, Jaime R. Merchan, Amita Patnaik, (unknown), Alexandra Drakaki, Moshe Chaim Ornstein, Bradley A. McGregor, Ralph J. Hauke, (unknown), Brian I. Rini, Pedro C. Barata, Paul Foster, Sutapa Mukhopadhyay, (unknown), (unknown), Manish Monga, Dimitry S.A. Nuyten, Sun Young Rha	0
5	First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial 2025 ·European Urology ·Martin H. Voss, Howard Gurney, Vagif Atduev, Cristina Suárez, Miguel Ángel Climent, David Pook, Piotr Tomczak, Philippe Barthélémy, Jae‐Lyun Lee, (unknown), V.P. Stus, Thomas Ferguson, Paweł Wiechno, Erhan Gökmen, Louis Lacombe, Craig Gedye, (unknown), (unknown), Joseph E. Burgents, Laurence Albigès	0
6	Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer 2024 ·JAMA Oncology ·Randy F. Sweis, Pablo Gajate, Rafael Morales‐Barrera, Jae‐Lyun Lee, Andrea Necchi, Filippo de Braud, Nicolas Penel, Viktor Grünwald, Marco Maruzzo, Johannes Meran, (unknown), Weichao Bao, Yinghui Zhou, Peter Ellinghaus, Jonathan E. Rosenberg	6
7	IFITM3-mediated activation of TRAF6/MAPK/AP-1 pathways induces acquired TKI resistance in clear cell renal cell carcinoma 2024 ·Investigative and Clinical Urology ·(unknown), (unknown), Sun Young Yoon, Hee Sang Hwang, Heounjeong Go, Dong‐Myung Shin, Hyein Ju, Chang Ohk Sung, Jae‐Lyun Lee, (unknown), Yong Mee Cho	2
8	Early stage adrenocortical carcinoma—what contributes to poor prognosis after adrenalectomy? A retrospective cohort study 2024 ·Annals of Surgical Treatment and Research ·D Kwon, (unknown), (unknown), (unknown), Jae Won Cho, Won Woong Kim, Yu‐Mi Lee, Jae‐Lyun Lee, Dong Eun Song, Ki‐Wook Chung, Tae‐Yon Sung	1
9	Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice 2023 ·Yonsei Medical Journal ·Kwonoh Park, Jin Young Kim, Inkeun Park, Seong Hoon Shin, Hyo Jin Lee, Jae‐Lyun Lee	3
10	Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy 2022 ·European Journal of Cancer ·Jeffrey Graham, J. Connor Wells, Shaan Dudani, Chun Loo Gan, Frede Donskov, Jae‐Lyun Lee, Christian Kollmannsberger, Luís Meza, Benoit Beuselinck, Aaron R. Hansen, Scott North, Georg A. Bjarnason, Nicolas Sayegh, Ravindran Kanesvaran, Lori Wood, Sébastien J. Hotte, Rana R. McKay, Toni K. Choueiri, Daniel Y.C. Heng	20
11	Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data 2022 ·European Journal of Cancer ·Laurence Albigès, Daniel Y.C. Heng, Jae‐Lyun Lee, Stephen Walker, Anders Mellemgaard, Lone H. Ottesen, Melanie M. Frigault, Anne L’Hernault, (unknown), Toni K. Choueiri, Mathilde Cancel, Sabina Signoretti	7
12	Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma breakdown → 2021 ·Journal of Clinical Oncology ·David F. McDermott, Jae‐Lyun Lee, Marek Ziobro, Cristina Suárez, (unknown), В. Б. Матвеев, Paweł Wiechno, Rustem Gafanov, Piotr Tomczak, Frédéric Pouliot, Frede Donskov, B. Yа. Alekseev, Sang Joon Shin, Georg A. Bjarnason, Daniel Castellano, Rachel Kloss Silverman, Rodolfo F. Perini, Charles Schloss, Michael B. Atkins	183
13	Construction of a Retrospective Cohort to Observe 10-Year Urologic Cancer Treatment Trends at the Biggest Medical Center of South Korea 2021 ·Se Young Choi, (unknown), Bumjin Lim, Jong Won Lee, Young Seok Kim, Jeong Kon Kim, Jae‐Lyun Lee, Yong Mee Cho, (unknown), In Gab Jeong, Cheryn Song, Jun Hyuk Hong, Choung‐Soo Kim, Hanjong Ahn, Bumsik Hong	1
14	Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma 2020 ·European Urology ·Bimal Bhindi, Jeffrey Graham, J. Connor Wells, Ziad Bakouny, Frede Donskov, Anna Paola Fraccon, Felice Pasini, Jae‐Lyun Lee, Naveen S. Basappa, Aaron R. Hansen, Christian Kollmannsberger, Ravindran Kanesvaran, Takeshi Yuasa, D. Scott Ernst, Sandy Srinivas, Brian I. Rini, I. Alex Bowman, Sumanta K. Pal, Toni K. Choueiri, Daniel Y.C. Heng	42
15	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma breakdown → 2017 ·New England Journal of Medicine ·Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin	2374
16	Cross-Sectional Study of Imatinib Plasma Trough Levels in Patients With Advanced Gastrointestinal Stromal Tumors: Impact of Gastrointestinal Resection on Exposure to Imatinib 2010 ·Journal of Clinical Oncology ·Changhoon Yoo, Min‐Hee Ryu, Byung Woog Kang, Shinkyo Yoon, Baek‐Yeol Ryoo, Heung-Moon Chang, Jae‐Lyun Lee, (unknown), (unknown), Yoon‐Koo Kang	73
17	Oxaliplatin and UFT, leucovorin combination chemotherapy in patients with advanced colorectal cancer. 2004 ·The Korean Journal of Internal Medicine ·(unknown), Soyeon Kim, (unknown), (unknown), Jiyoung Kim, (unknown), (unknown), (unknown), Hun-Mo Ryoo, Hanil Lee, Im-Hee Shin, Min Kyoung Kim, Jae‐Lyun Lee, Kyunghee Lee, (unknown)	1
18	Survival according to Treatment Modalities in 137 Patients with Aplastic Anemia 2003 ·Blood Research ·Hee-Jung Sohn, (unknown), (unknown), (unknown), (unknown), Eun-Kyung Kim, Gyeong‐Won Lee, Jae‐Lyun Lee, Min‐Hee Ryu, Seong‐Jun Choi, Je‐Hwan Lee, Sung‐Bae Kim, Sang‐We Kim, Kyoo‐Hyung Lee, Jung‐Shin Lee, Woo-Kun Kim, Cheolwon Suh	0
19	Brain metastasis : Clinical characteristics and prognosis 2002 ·The Korean Journal of Internal Medicine ·Jae‐Lyun Lee, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Kyung-Hee Lee, (unknown), (unknown), (unknown)	1
20	A Case of Pure Red Cell Aplasia Associated with B-cell Chronic Lymphocytic Leukemia 2002 ·Blood Research ·Jae‐Lyun Lee, (unknown), (unknown), (unknown), Kyunghee Lee, (unknown), Hyun‐Mo Ryoo	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact